ABBV Stock Overview
A research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
AbbVie Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$30.72 |
| 52 Week High | US$31.00 |
| 52 Week Low | US$22.44 |
| Beta | 0.60 |
| 1 Month Change | 11.43% |
| 3 Month Change | 21.86% |
| 1 Year Change | 16.06% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 29.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| ABBV | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 2.1% | -4.3% | -2.1% |
| 1Y | 16.1% | 8.9% | 9.6% |
Return vs Industry: ABBV exceeded the Canadian Biotechs industry which returned 8.9% over the past year.
Return vs Market: ABBV exceeded the Canadian Market which returned 9.6% over the past year.
Price Volatility
| ABBV volatility | |
|---|---|
| ABBV Average Weekly Movement | 3.2% |
| Biotechs Industry Average Movement | 11.8% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in CA Market | 17.6% |
| 10% least volatile stocks in CA Market | 3.2% |
Stable Share Price: ABBV has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: ABBV's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 55,000 | Robert Michael | www.abbvie.com |
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products.
AbbVie Inc. Fundamentals Summary
| ABBV fundamental statistics | |
|---|---|
| Market cap | CA$553.20b |
| Earnings (TTM) | CA$6.13b |
| Revenue (TTM) | CA$81.48b |
89.0x
P/E Ratio6.7x
P/S RatioIs ABBV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABBV income statement (TTM) | |
|---|---|
| Revenue | US$56.33b |
| Cost of Revenue | US$16.73b |
| Gross Profit | US$39.61b |
| Other Expenses | US$35.37b |
| Earnings | US$4.24b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.40 |
| Gross Margin | 70.31% |
| Net Profit Margin | 7.52% |
| Debt/Equity Ratio | 1,994.8% |
How did ABBV perform over the long term?
See historical performance and comparisonDividends
3.1%
Current Dividend Yield263%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/11 21:54 |
| End of Day Share Price | 2025/03/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AbbVie Inc. is covered by 47 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| Luisa Hector | Berenberg |